An observational study in Hepatitis B, sponsored by Kirby Institute. Recruiting at 19 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by Kirby Institute · Observational
The REACH-B study establishes an observational cohort study of people living with chronic hepatitis B from a national network, including a diverse range of services, to characterise and monitor hepatitis B linkage to care and treatment requirements amongst this population.
Participants presenting to participating clinics for HBV care within the previous 12 months will be identified and enrolment data will be collected including demographics, laboratory parameters, liver disease assessment, treatment history and clinical management. Follow-up data on HBV treatment and clinical management, liver disease stage and laboratory parameters will be collected at each subsequent visit or at minimum every 12 months.
1,045 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 365 across 251 observational studies indexed under Hepatitis B.
Browse Hepatitis B studies →Kirby Institute is the lead sponsor of 94 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults diagnosed with chronic HBV as defined by a positive HBsAg result at participating sites will be enrolled in the cohort. Participants can be newly diagnosed or existing patients of the service. Data on HBV disease status, liver disease status, HBV monitoring and treatment will be collected six monthly from enrolment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Nil
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with chronic hepatitis B infection as defined by HBV surface antigen positive
Other: No intervention
No intervention
Characterisation of HBV
To characterise and monitor hepatitis B linkage to care and treatment requirements amongst people living with chronic hepatitis B
Time frame: July 2027
Socio-demographics of HBV infected population
To characterise the socio-demographic spectrum of people living with chronic HBV
Time frame: July 2027
HBV Disease staging
To assess the proportion of individuals in each phase of the disease, based on the natural history of hepatitis B infection
Time frame: July 2027
HBV Care Cascade
To assess the proportion of individuals who are eligible for each recommended hepatitis B clinical care level
Time frame: July 2027
HBV Treatment and Care
To monitor the uptake of recommended hepatitis B clinical care, including antiviral treatment
Time frame: July 2027
HBV Care and treatment adherence
To monitor the adherence to recommended hepatitis B care, including the patterns of antiviral use and cessation
Time frame: July 2027
HCC Surveillance
To assess the rate of surveillance for hepatocellular carcinoma
Time frame: July 2027
HBV Disease Progression
To assess the rate of progression from each phase to the subsequent phase of hepatitis B
Time frame: July 2027
Liver fibrosis progression
To assess the rate of liver fibrosis progression, including the development of cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma
Time frame: July 2027
Not enrolling at this site.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2022 (actual). Primary completion is estimated for Jul 2030, 101 months after the start.
Of 69 non-industry observational studies under Hepatitis B, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 126. This study's planned 101 months is above that.
Counting every sponsor, half of 81 studies reached it within 55 months; a quarter within 17 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kirby Institute